Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Groupe

Jordan M. Schmitt, Scott R. Sommers, William Fisher, Rafat Ansari, Erwin Robin, Karuna Koneru, John McClean, Ziyue Liu, Yan Tong, Nasser Hanna

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The combination of sunitinb (37.5 mg orally daily) + paclitaxel (90 mg/m intravenously on days 1, 8, 15 every 4 weeks) was examined in patients with advanced esophageal or gastroesophageal junction cancer, and progression-free survival (PFS) was compared to that of historical controls. The end points included response rate, overall survival, and toxicities. Twenty-eight patients were enrolled at six centers. Median age was 59.5 years. The 24-week PFS rate was 25% (90% confidence interval [CI], 12-42%). Three (11%) of 23 evaluable patients had a response (1 complete response and 2 partial response) (90% CI, 3-25%). Median overall survival was 228 days (90% CI, 140-283 days). Grade 3/4 toxicities included leukopenia/neutropenia (25%), anemia (18%), fatigue (11%), and hemorrhage (11%). There were four grade 5 toxicities including upper gastrointestinal hemorrhage (n = 2), gastrointestinal/esophageal fistula (n = 1), and unexplained death (n = 1). In our study, we found that sunitinib + paclitaxel in patients with advanced esophageal or gastroesophageal junction cancer had a 24-week PFS no better than the PFS of historical controls. The combination also had a high rate of serious toxicities and will not be pursued.

Original languageEnglish
Pages (from-to)760-763
Number of pages4
JournalJournal of Thoracic Oncology
Volume7
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Esophageal Neoplasms
Paclitaxel
Disease-Free Survival
Esophagogastric Junction
Confidence Intervals
Survival Rate
Esophageal Fistula
Gastrointestinal Hemorrhage
Leukopenia
Neutropenia
Fatigue
Anemia
Neoplasms
Hemorrhage
Survival
sunitinib

Keywords

  • Angiogenesis
  • Esophageal
  • Gastroesophageal junction
  • Paclitaxel
  • Sunitinib
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Sunitinib plus paclitaxel in patients with advanced esophageal cancer : A phase II study from the Hoosier Oncology Groupe. / Schmitt, Jordan M.; Sommers, Scott R.; Fisher, William; Ansari, Rafat; Robin, Erwin; Koneru, Karuna; McClean, John; Liu, Ziyue; Tong, Yan; Hanna, Nasser.

In: Journal of Thoracic Oncology, Vol. 7, No. 4, 04.2012, p. 760-763.

Research output: Contribution to journalArticle

Schmitt, Jordan M. ; Sommers, Scott R. ; Fisher, William ; Ansari, Rafat ; Robin, Erwin ; Koneru, Karuna ; McClean, John ; Liu, Ziyue ; Tong, Yan ; Hanna, Nasser. / Sunitinib plus paclitaxel in patients with advanced esophageal cancer : A phase II study from the Hoosier Oncology Groupe. In: Journal of Thoracic Oncology. 2012 ; Vol. 7, No. 4. pp. 760-763.
@article{8a8f230017064291b359e59f75c099be,
title = "Sunitinib plus paclitaxel in patients with advanced esophageal cancer: A phase II study from the Hoosier Oncology Groupe",
abstract = "The combination of sunitinb (37.5 mg orally daily) + paclitaxel (90 mg/m intravenously on days 1, 8, 15 every 4 weeks) was examined in patients with advanced esophageal or gastroesophageal junction cancer, and progression-free survival (PFS) was compared to that of historical controls. The end points included response rate, overall survival, and toxicities. Twenty-eight patients were enrolled at six centers. Median age was 59.5 years. The 24-week PFS rate was 25{\%} (90{\%} confidence interval [CI], 12-42{\%}). Three (11{\%}) of 23 evaluable patients had a response (1 complete response and 2 partial response) (90{\%} CI, 3-25{\%}). Median overall survival was 228 days (90{\%} CI, 140-283 days). Grade 3/4 toxicities included leukopenia/neutropenia (25{\%}), anemia (18{\%}), fatigue (11{\%}), and hemorrhage (11{\%}). There were four grade 5 toxicities including upper gastrointestinal hemorrhage (n = 2), gastrointestinal/esophageal fistula (n = 1), and unexplained death (n = 1). In our study, we found that sunitinib + paclitaxel in patients with advanced esophageal or gastroesophageal junction cancer had a 24-week PFS no better than the PFS of historical controls. The combination also had a high rate of serious toxicities and will not be pursued.",
keywords = "Angiogenesis, Esophageal, Gastroesophageal junction, Paclitaxel, Sunitinib, Tyrosine kinase inhibitors",
author = "Schmitt, {Jordan M.} and Sommers, {Scott R.} and William Fisher and Rafat Ansari and Erwin Robin and Karuna Koneru and John McClean and Ziyue Liu and Yan Tong and Nasser Hanna",
year = "2012",
month = "4",
doi = "10.1097/JTO.0b013e31824abc7c",
language = "English",
volume = "7",
pages = "760--763",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "4",

}

TY - JOUR

T1 - Sunitinib plus paclitaxel in patients with advanced esophageal cancer

T2 - A phase II study from the Hoosier Oncology Groupe

AU - Schmitt, Jordan M.

AU - Sommers, Scott R.

AU - Fisher, William

AU - Ansari, Rafat

AU - Robin, Erwin

AU - Koneru, Karuna

AU - McClean, John

AU - Liu, Ziyue

AU - Tong, Yan

AU - Hanna, Nasser

PY - 2012/4

Y1 - 2012/4

N2 - The combination of sunitinb (37.5 mg orally daily) + paclitaxel (90 mg/m intravenously on days 1, 8, 15 every 4 weeks) was examined in patients with advanced esophageal or gastroesophageal junction cancer, and progression-free survival (PFS) was compared to that of historical controls. The end points included response rate, overall survival, and toxicities. Twenty-eight patients were enrolled at six centers. Median age was 59.5 years. The 24-week PFS rate was 25% (90% confidence interval [CI], 12-42%). Three (11%) of 23 evaluable patients had a response (1 complete response and 2 partial response) (90% CI, 3-25%). Median overall survival was 228 days (90% CI, 140-283 days). Grade 3/4 toxicities included leukopenia/neutropenia (25%), anemia (18%), fatigue (11%), and hemorrhage (11%). There were four grade 5 toxicities including upper gastrointestinal hemorrhage (n = 2), gastrointestinal/esophageal fistula (n = 1), and unexplained death (n = 1). In our study, we found that sunitinib + paclitaxel in patients with advanced esophageal or gastroesophageal junction cancer had a 24-week PFS no better than the PFS of historical controls. The combination also had a high rate of serious toxicities and will not be pursued.

AB - The combination of sunitinb (37.5 mg orally daily) + paclitaxel (90 mg/m intravenously on days 1, 8, 15 every 4 weeks) was examined in patients with advanced esophageal or gastroesophageal junction cancer, and progression-free survival (PFS) was compared to that of historical controls. The end points included response rate, overall survival, and toxicities. Twenty-eight patients were enrolled at six centers. Median age was 59.5 years. The 24-week PFS rate was 25% (90% confidence interval [CI], 12-42%). Three (11%) of 23 evaluable patients had a response (1 complete response and 2 partial response) (90% CI, 3-25%). Median overall survival was 228 days (90% CI, 140-283 days). Grade 3/4 toxicities included leukopenia/neutropenia (25%), anemia (18%), fatigue (11%), and hemorrhage (11%). There were four grade 5 toxicities including upper gastrointestinal hemorrhage (n = 2), gastrointestinal/esophageal fistula (n = 1), and unexplained death (n = 1). In our study, we found that sunitinib + paclitaxel in patients with advanced esophageal or gastroesophageal junction cancer had a 24-week PFS no better than the PFS of historical controls. The combination also had a high rate of serious toxicities and will not be pursued.

KW - Angiogenesis

KW - Esophageal

KW - Gastroesophageal junction

KW - Paclitaxel

KW - Sunitinib

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84863364424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863364424&partnerID=8YFLogxK

U2 - 10.1097/JTO.0b013e31824abc7c

DO - 10.1097/JTO.0b013e31824abc7c

M3 - Article

C2 - 22425927

AN - SCOPUS:84863364424

VL - 7

SP - 760

EP - 763

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 4

ER -